SCHEMBL26424678

SCHEMBL26424678

Cc1ccc(-c2cnc(CSc3nc(C)cc(N)n3)o2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 7/20 0.54
▸ NPC1 O15118 6/20 0.54
▸ SMN1; SMN2 Q16637 5/20 0.54
▸ LMNA P02545 3/20 0.54
▸ HTT P42858 2/20 0.54
▸ ALDH1A1 P00352 5/20 0.51
▸ HPGD P15428 3/20 0.51
▸ USP2 O75604 1/20 0.51
▸ TSHR P16473 4/20 0.38
▸ MAPT P10636 2/20 0.38
▸ NPSR1 Q6W5P4 2/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ CCNE2 O96020 1/20 0.38
▸ CDK4 P11802 1/20 0.38
▸ CCND1 P24385 1/20 0.38
▸ CCNE1 P24864 1/20 0.38
▸ CDK2 P24941 1/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ CLK1 P49759 1/20 0.37
▸ GFER P55789 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31494305 1.00 RAB9A (0.54) RAB9ANPC1SMN1; SMN2LMNAHTT
SCHEMBL27218845 0.91 ALDH1A1 (0.49) RAB9ANPC1SMN1; SMN2LMNAHTT
SCHEMBL26424620 0.91 SMN1; SMN2 (0.49) RAB9ANPC1SMN1; SMN2LMNAHTT
SCHEMBL31494346 0.91 ALDH1A1 (0.49) RAB9ANPC1SMN1; SMN2LMNAHTT
SCHEMBL31494335 0.91 SMN1; SMN2 (0.49) RAB9ANPC1SMN1; SMN2LMNAHTT
SCHEMBL27218700 0.91 SMN1; SMN2 (0.62) RAB9ANPC1SMN1; SMN2LMNAHTT
SCHEMBL31494316 0.91 SMN1; SMN2 (0.62) RAB9ANPC1SMN1; SMN2LMNAHTT
SCHEMBL31494329 0.89 HTT (0.52) RAB9ANPC1SMN1; SMN2LMNAHTT
SCHEMBL27218829 0.89 HTT (0.52) RAB9ANPC1SMN1; SMN2LMNAHTT
SCHEMBL31494384 0.86 SMN1; SMN2 (0.50) RAB9ANPC1SMN1; SMN2LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4232448-B1 AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR Halo Therapeutics Ltd (GB) 2025-05-07 — — EP claimed
EP-3956323-B1 OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1 Halo Therapeutics Ltd (GB) 2025-03-05 — — EP claimed
EP-4232448-B1 AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR Halo Therapeutics Ltd (GB) 2025-05-07 — — EP disclosed
EP-3956323-B1 OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1 Halo Therapeutics Ltd (GB) 2025-03-05 — — EP disclosed
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor Halo Therapeutics Ltd (GB) 2024-05-16 — — US disclosed
US-20230128972-A1 Anat Inhibitors and Methods of Use Thereof Atomwise Inc. 2023-04-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230128972-A1 Anat Inhibitors and Methods of Use Thereof AANAT, CHAT, NAT1 RAB9A 2492/4885NPC1 305/4885SMN1; SMN2 2713/4885
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor FFAR1, FFAR2, FFAR3 RAB9A 2474/4885NPC1 781/4885SMN1; SMN2 1802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback